Skip to Main Content
PFF Help Center
(844) 825-5733
Facebook
LinkedIn
YouTube
Instagram
Join the PFF Registry
Donate
Shop PFF
Menu
Understanding PF
Newly Diagnosed: Start Here
PF Basics: Info for Newly Diagnosed Patients
About Pulmonary Fibrosis
What is Pulmonary Fibrosis?
Causes
Diagnosis
Symptoms
Glossary and Abbreviations
Types of Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Environmental
Occupational
Drug-Induced
Radiation-Induced
Autoimmune Connective Tissue Disease
Other Types of Pulmonary Fibrosis
Treatment Options
Supplemental Oxygen
Pulmonary Rehabilitation
Pulmonary Rehabilitation Toolkit
Symptom Management
Medication
Lung Transplantation
Patients & Caregivers
Medical and Support Resources
Find Medical Care
Find a Support Group
PFF Help Center
Pulmonary Rehabilitation Toolkit
For the Caregiver
Stories from the Heart
Clinical Trials
Medical Statements
Education Resources
Fact Sheets
Maintain Your Health
Videos
Webinars
Telemedicine
Educational Materials
Recursos de fibrosis pulmonar
PFF Insights Blog
Clinical Trials Blog
PFF Summit
Oxygen Therapy
What is Oxygen Therapy?
Benefits
Oxygen Rights and Resources
Oxygen Therapy FAQs
Join a Research Study
PFF Community Registry
APPLe Familial Pulmonary Fibrosis Study
PRECISIONS
Find a clinical trial
Researchers & Healthcare Providers
Clinical Resources
PFF Clinical Resource Hub
Webinars
CME/CE Library
Position Statements
Educational Materials
PFF Summit
Fact Sheets
Research Opportunities
PFF Community Registry
PFF Scholars and Other Research Opportunities
Familial Pulmonary Fibrosis Research Award
PROLIFIC
Community Engagement
Care Center Network
Nurse and Allied Health Network
Host an Event
Book a PFF Ambassador
Request Sponsorship Support
Ways to Give
Ways to Give
Workplace & Matching Giving
Planned Giving
Donor Advised Funds
Donate Stocks & Bonds
Qualified Charitable Distribution (QCD)
Donate Cryptocurrency
Donation FAQs
2026 Tax Law Changes
Albert Rose Legacy Society
Shop PFF
Honor and Memorial Giving
Make a Gift in Honor or Memory
Find a Tribute
Create a Tribute
Fundraising Events
PFF Walk
Broadway Belts for PFF!
Team PFF
Community Walk
Corporate Giving
Corporate Partners
PFF Corporate Committee
Donate Today
Mail-in Donations
Donate Monthly
Get Involved
Events
Attend an Event
Fundraise with Team PFF
Fundraising on Facebook
PFF Walk
PFF Summit 2025
Broadway Belts for PFF!
ILD Day
PFF Education Symposium
Let's Talk Cough
Volunteer
Join the PFF Community Registry
Start a Support Group
Be a PFF Advocate
Share Your Story
Become a PFF Ambassador
PF Awareness Month
Join a Board Committee
Shop PFF
PFF Walk
About the PFF Walk
Bay Area
Chicago
Dallas
National Walk Day
NYC Metro
Pittsburgh
Tampa
Washington, D.C.
Join the PFF Registry
What is the PFF Registry
Getting started
Submit a research proposal
History of the PFF Registry
Registry Report
Meet The Team
Sponsors
FAQ
About Us
Who We Are
Leadership
Mission & History
Medical Advisory Committees
Financials
Our 25 year anniversary
What We Do
The PFF is Me Strategic Plan
Patient Support Programs
Policy & Advocacy
PFF Funded Research
Education
News and Media
News
PFF In The Media
Breathe Bulletin
Media Resources
Careers
Contact Us
Search
Search
External News
Home
External News
FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD
March 09, 2021
Feasibility, Safety, and Tolerance of Mesenchymal Stem Cell Therapy for Obstructive Chronic Lung Allograft Dysfunction
March 09, 2021
After decades of work, UVA launches human tests of lung transplant drug.
March 09, 2021
Boehringer Ingelheim Expands Idiopathic Pulmonary Fibrosis (IPF) Pipeline Through Collaboration and License Agreement with Bridge Biotherapeutics
March 09, 2021
Indalo Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead Antifibrotic Drug Candidate IDL-2965
March 09, 2021
New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years with consistent safety
March 09, 2021
FDA Approves Boehringer Ingelheim’s OFEV® (nintedanib) as First Kinase Inhibitor to Treat Idiopathic Pulmonary Fibrosis
March 09, 2021
Promedior Received Breakthrough Therapy Designation from FDA for PRM-151 in Idiopathic Pulmonary Fibrosis
March 09, 2021
Promedior Announces Positive Long-term Safety and Efficacy Data from Open Label Extension Study of PRM-151 in Idiopathic Pulmonary Fibrosis
March 09, 2021
GLPG1690 halts disease progression in IPF patients in FLORA Phase 2a trial
March 09, 2021
Galapagos announces ISABELA Phase 3 program in IPF
March 09, 2021
IND application of ND-L02-s0201 allowed to proceed for idiopathic pulmonary fibrosis indication by the FDA
March 09, 2021
BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis
March 09, 2021
Breath Therapeutics announces initiation of global Phase 3 trials for the treatment of bronchiolitis obliterans syndrome
March 09, 2021
FibroGen Announces First Patient Dosed in ZEPHYRUS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients with Idiopathic Pulmonary Fibrosis
March 09, 2021
Galecto Biotech's lead molecule TD139 is safe, well tolerated, with direct target engagement and biomarker effects in a clinical Phase 1b/2a trial in IPF patients
March 09, 2021
Gilead and Galapagos enter into transformative research and development collaboration
March 09, 2021
Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study
March 09, 2021
Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial
March 09, 2021
FDA Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease
March 09, 2021
1
2
3
4
5
6
7
8
9
